key: cord-0296910-lbd6hn57
authors: Zhang, Zeli; Mateus, Jose; Coelho, Camila H.; Dan, Jennifer M.; Moderbacher, Carolyn Rydyznski; Gálvez, Rosa Isela; Cortes, Fernanda H.; Grifoni, Alba; Tarke, Alison; Chang, James; Escarrega, E. Alexandar; Kim, Christina; Goodwin, Benjamin; Bloom, Nathaniel I.; Frazier, April; Weiskopf, Daniela; Sette, Alessandro; Crotty, Shane
title: Humoral and cellular immune memory to four COVID-19 vaccines
date: 2022-05-27
journal: nan
DOI: 10.1016/j.cell.2022.05.022
sha: 33586c74ce0051f71447702baa91cde68ce79c56
doc_id: 296910
cord_uid: lbd6hn57

Multiple COVID-19 vaccines, representing diverse vaccine platforms, successfully protect against symptomatic COVID-19 cases and deaths. Head-to-head comparisons of T cell, B cell, and antibody responses to diverse vaccines in humans are likely to be informative for understanding protective immunity against COVID-19, with particular interest in immune memory. Here, SARS-CoV-2-spike-specific immune responses to Moderna mRNA-1273, Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S and Novavax NVX-CoV2373 were examined longitudinally for 6 months. 100% of individuals made memory CD4+ T cells, with cTfh and CD4-CTL highly represented after mRNA or NVX-CoV2373 vaccination. mRNA vaccines and Ad26.COV2.S induced comparable CD8+ T cell frequencies, though only detectable in 60-67% of subjects at 6 months. A differentiating feature of Ad26.COV2.S immunization was a high frequency of CXCR3+ memory B cells. mRNA vaccinees had substantial declines in antibodies, while memory T and B cells were comparatively stable. These results may also be relevant for insights against other pathogens.

Multiple COVID-19 vaccines, representing diverse vaccine platforms, successfully protect against symptomatic 23 COVID-19 cases and deaths. Head-to-head comparisons of T cell, B cell, and antibody responses to diverse vaccines 24 in humans are likely to be informative for understanding protective immunity against COVID-19, with particular 25 interest in immune memory. Here, SARS-CoV-2-spike-specific immune responses to Moderna mRNA-1273, 26

Pfizer/BioNTech BNT162b2, Janssen Ad26.COV2.S and Novavax NVX-CoV2373 were examined longitudinally for 6 27 months. 100% of individuals made memory CD4 + T cells, with cTfh and CD4-CTL highly represented after mRNA or 28 NVX-CoV2373 vaccination. mRNA vaccines and Ad26.COV2.S induced comparable CD8 + T cell frequencies, though 29 only detectable in 60-67% of subjects at 6 months. A differentiating feature of Ad26.COV2.S immunization was a 30 high frequency of CXCR3 + memory B cells. mRNA vaccinees had substantial declines in antibodies, while memory T 31 and B cells were comparatively stable. These results may also be relevant for insights against other pathogens. Figures S1B-D). 144 For Ad26.COV2.S 1-dose immunization, 86% of vaccinees had detectable Spike IgG and 79% RBD IgG at T2 145 (Figures 2A-B) . 64% of vaccinees had detectable neutralizing antibodies at T2, which was somewhat lower than the 146 86% with mRNA-1273 and 76% with BNT162b2 ( Figure 2C ). Ad26.COV2.S antibody binding and neutralization titers 147 gradually increased over time, with 100% of recipients having detectable Spike IgG, RBD IgG, and neutralizing 148 antibodies at 6-month post-immunization. Ad26.COV2.S neutralizing antibody titers peaked at T5 (GMT 58), but that 149 peak was still 24-fold lower than the mRNA-1273 peak (GMT 1,399) and 16-fold lower than the BNT162b2 peak (GMT 150 903). At 6-month post-immunization, Ad26.COV2.S neutralizing antibody titers were 3.6-fold lower than mRNA-1273 151 and 2.4-fold lower than BNT162b2 ( Figure 2C ). Over the entire 6-month time period, Ad26.COV2.S spike IgG, RBD 152

IgG, and neutralizing antibody titers were significantly lower than mRNA vaccine recipients (p<0.0001 mRNA-1273, 153

p<0.0001 BNT162b2. Figures S1B-D) . 154 For NVX-CoV2373, antibody titers were available for 3.5 and 6 months. Spike and RBD IgG titers were 155 substantial at 3.5 months post-vaccination and were marginally (not significantly) decreased at T5 (Figures 2A-B) . 156 Neutralizing antibody titers were comparable at both timepoints ( Figure 2C ). At 6-month post-immunization, NVX-157

CoV2373 neutralizing antibody titers (GMT 152) were 2.6-fold higher than Ad26.COV2.S (GMT 58), and were 158 comparable to mRNA-1273 (GMT 209) and BNT162b2 (GMT 140). Considering the 3.5-month to 6-month period in 159 aggregate, RBD IgG and neutralizing antibody titers in NVX-CoV2373 recipients were comparable to both mRNA 160 vaccines (Figures S1F-G) . Spike IgG decay rates at the final time point were comparable for NVX-CoV2373, mRNA-161 1273 and BNT162b2 (t1/2 were 52, 68, and 69 days respectively. 95% Cls: 37-88, 59-81, and 60-82 days). 162

Lastly, antibody titers at 6 months were compared to SARS-CoV-2 infected subjects (Figures 2D-F) who were 163 enrolled for a previously reported study . The previously infected individuals were selected 164 randomly. Recipients of the mRNA vaccines (mRNA-1273 and BNT162b2) had 4.5-fold higher spike IgG (Figure 2D) , 165 6.4-fold higher RBD IgG (Figure 2E) , and 3.4-fold higher neutralizing antibody titers ( Figure 2F ) compared to 166 previously-infected subjects. Antibody titers from NVX-CoV2373 recipients also trended higher than SARS-CoV-2 167 infected subjects (Figures 2D-F) . Antibody titers from Ad26.COV2.S were similar to titers from SARS-CoV-2 infected 168 subjects (Figures 2D-F) . 169 Overall, antibody titers were significantly higher for mRNA recipients than Ad26.COV2.S recipients. 170

Recipients of NVX-Co2373 immunization also had higher peak antibody titers than recipients of Ad26.COV2.S. 171

Antibody titers to mRNA-1273, BNT162b2, and Ad26.COV2.S changed substantially over the 6+ months of 172 observation, with different patterns seen for the mRNA versus adenoviral vector platforms. 173 174

Spike-specific CD4 + T cell memory elicited by four different vaccines 175 SARS-CoV-2 spike-specific CD4 + T cell responses were measured for all donors at all available timepoints 176 utilizing two previously described flow cytometry activation-induced marker (AIM) assays (OX40 + CD137 + and OX40 + 177 surface CD40L + (sCD40L)) ( Figures 3A-B , and S2) and separate intracellular staining (ICS) for cytokines (IFN, TNF,  178 IL-2), granzyme B (GzB), and intracellular CD40L (iCD40L) (Figure 4) . SARS-CoV-2 spike-specific circulating follicular 179 helper T (cTfh) cells were measured at all time points (Figures 3C and S2D) , as this subpopulation of CD4 + T cells is 180 crucial for supporting antibody responses following vaccination ( In response to a single dose of the mRNA-1273 vaccine (T2), a majority of subjects developed a spike-specific 183

CD4 + T cell response as measured by both AIM + (Figures 3A-B) and iCD40L + secreted-effector + (ICS + ) CD4 + T cells 184 (Figure 4A-B) . Spike-specific CD4 + T cell responses peaked after the 2 nd mRNA-1273 vaccination (100% responders, 185 T3) and were well maintained out to 6 months post-vaccination, with only a 1.1-to 1.9-fold reduction in AIM + or ICS + 186

CD4 + T cells, respectively (Figures 3A-B and 4A-B) . mRNA-1273 vaccination induced spike-specific cTfh cells in most 187 donors after the 1 st dose, which peaked after the 2 nd dose (97%, T3), and memory cTfh cells were maintained out to 188 6 months post-vaccination with only a 1.8-fold change from peak (T3 to T5, Figure 3C ). Memory cTfh cells 189

represented 27% of the spike-specific memory CD4 + T cells, on average. 190 Vaccination with BNT162b2 induced spike-specific AIM + and ICS + CD4 + T cells after the first vaccination (T2), 191 with peak responses after the 2 nd immunization (T3). However, peak responses to BNT162b2 vaccination were 192 significantly lower than mRNA-1273 peak vaccine responses both by AIM and ICS (1.5-fold lower, P=0.023; and 2. fold lower, P=0.0075. Figures 3A and 4) . Memory CD4 + T cells were detectable in 86-100% of BNT162b2 vaccinees 194 at 6 months after immunization, but the memory CD4 + T cell frequencies were significantly lower than for mRNA-195 J o u r n a l P r e -p r o o f 5 1273 (1.8-fold lower by AIM, P=0.014 and 2.6-fold lower by ICS, P=0.0148. Figures 3A and 4) . Spike-specific memory 196 cTfh cell frequencies were comparable between BNT162b2 and mRNA-1273 vaccination ( Figure 3C) . 197 Both mRNA-1273 and BNT162b2 vaccination induced ICS + spike-specific memory CD4 + T cells, including 198 iCD40L + IFN + , iCD40L + TNF + , and iCD40L + IL-2 + cells, detectable out to 6 months post-vaccination. mRNA-1273 199 vaccinees had significantly higher frequencies of TNF + and IL-2 + CD4 + T cells at all timepoints and higher levels of 200 IFN + memory CD4 + T cells at 6 months relative to BNT162b2 vaccinees (Figure 4) . GzB + CD4 + T cells (iCD40L + GzB + ) 201

were assessed as indicators of CD4 + cytotoxic T lymphocytes (CD4-CTL). Interestingly, both mRNA vaccines generated 202

GzB + CD4 + T cells as a significant fraction of the overall spike-specific CD4 + T cell response (Figures 4G and S3) . 203 Multifunctional spike-specific CD4 + T cells were observed after the 1 st dose of either mRNA-1273 or BNT162b2, and 204 multifunctionality was stably maintained out to 6 months (Figures 4B and S3) . 205 For the Ad26.COV2.S vaccine, spike-specific CD4 + T cell responses were detectable in a majority of 206 individuals and were largely stable out to 6 months post-vaccination (71-100% of individuals with spike-specific CD4 + 207

T cells by AIM assays; 43% with spike-specific CD4 + T cells by ICS (Figures 3A-B and 4) . cTfh cells were detectable in 208 the majority of individuals ( Figure 3C ). Peak CD4 + T cell responses were lower to Ad26.COV2.S than either of the 209 mRNA vaccines. Peak AIM + CD4 + T cells to Ad26.COV2.S were 2.2-to 2.4-fold lower than BNT162b2 and 3.4-to 3.2-210 fold lower than mRNA-1273 peak responses (Figures 3A-B) . Peak spike-specific ICS + CD4 + T cell responses to 211

Ad26.COV2.S were 6.1-fold lower than BNT162b2 and 15-fold lower than mRNA-1273 ( Figure 4B ). Both mRNA 212 vaccines generated significantly higher peak frequencies of IFN + CD4 + T cells than Ad26.COV2.S vaccination 213 (iCD40L + IFN + , mRNA1273 P<0.0001, BNT162b2 P=0.007), and mRNA-1273 vaccinees had significantly higher IFN + 214 spike-specific memory CD4 + T cells than Ad26.COV2.S at 6 months post-vaccination (P=0.0009, Figure 4D ). The mRNA 215

vaccines also induced significantly more CD4-CTLs at peak than Ad26.COV2.S (mRNA1273 P<0.0001, BNT162b2 216 P=0.0012, Figure 4G ), and the CD4-CTLs induced by the mRNA vaccines were more sustained as memory cells at the 217 6-month memory timepoint relative to Ad26.COV2.S ( Figure 4G ). Spike-specific CD4 + T cells induced by Ad26.COV2.S 218 had less multifunctionality at all time points relative to both mRNA vaccines (>3 functions, T3 P=0.023, T4 P=0.017, 219 T5 P=0.023; Figures 4B and S3A) . Overall, memory CD4 + T cell frequencies were lower after Ad26.COV2.S 220 immunization compared to mRNA vaccines, assessed as total spike-specific memory (AIM + ), cTfh memory, IFN + 221 memory, CD4-CTL memory, or memory CD4 + T cell multifunctionality. 222

For the NVX-CoV2373 vaccine, 100% of immunized individuals developed spike-specific memory CD4 + T 223 cells detected by both AIM and ICS assays (Figures 3A-B and 4) . All NVX-CoV2373 immunized individuals had spike-224 specific memory cTfh cells ( Figure 3C ). Memory CD4 + T cell responses to NVX-CoV2373 were comparable in 225 magnitude to the mRNA vaccines by AIM (Figures 3A-B) . At 6 months post-vaccination, AIM + memory CD4 + T cell 226 frequencies appear to have stabilized, with no discernible half-life for all four vaccines. By ICS, NVX-CoV2373 227 responses 6 months post-vaccination were comparable to BNT162b2 (NVX-CoV2373 geomean 0.074%, BNT162b2 228 geomean 0.059%), and significantly higher than the Ad26.COV2.S vaccine (Ad26.COV2.S geomean 0.015%, P=0.0057. 229 Figure 4B ). NVX-CoV2373 induced multifunctional memory spike-specific CD4 + T cells comparably to both mRNA 230 vaccines (T4 and T5, Figures 4B and S3A) , with a shift in the relative abundance of IL-2 + cells over IFN + memory CD4 + 231 T cells observed for NVX-CoV2373 (Figures 4D and 4F) . 232

Spike-specific CD4 + T cell responses in COVID-19 recovered individuals were assessed to compare infection-233

induced versus vaccine-elicited T cell memory (Figures 3D-F and 4C) . Spike-specific CD4 + T cell memory at 6 months 234 post-vaccination in mRNA-1273 and NVX-CoV2373 vaccinees was significantly higher than for COVID-19 recovered 235 individuals, both by AIM and ICS (Figures 3D and 4C) . BNT162b2 and Ad26.COV2.S generated memory CD4 + T cells 236

frequencies not significantly different than SARS-CoV-2 infection (Figures 3D and 4C ). Memory cTfh cell frequencies 237

were similar between all four vaccines and infection ( Figure 3F) . Overall, all four of the COVID-19 vaccines generated 238 memory CD4 + T cells in the majority of vaccinated individuals, with representation of both Th1 (IFN + ) and Tfh 239 memory, with memory CD4-CTL also generated by mRNA and NVX-CoV2373 vaccines. Additionally, the magnitude 240 of spike-specific CD4 + T cell memory was generally higher for mRNA vaccines and NVX-CoV2373 than seen in COVID-241 19 recovered individuals. 242 243

Spike-specific CD8 + T cells elicited by four different vaccines 244 SARS-CoV-2 spike-specific CD8 + T cells were measured by ICS at all time points to identify IFN, TNF, or IL-245 2 producing cells (CD69 + cytokine + gating = "ICS + ". Figures 5 and S4 ) for all vaccine modalities. Spike-specific CD8 + T 246 cells were also measured by AIM (CD69 + CD137 + , Figure S4E -G). 247 J o u r n a l P r e -p r o o f For the mRNA-1273 vaccine, 83% of vaccinees had detectable spike-specific CD8 + T cell responses after the 248 1 st immunization ( Figure 5C ). ICS + CD8 + T cell response rates peaked after the 2 nd immunization (87% T3 responders, 249 Figure 5C ). Spike-specific memory CD8 + T cells were largely maintained out to 6 months after mRNA-1273 vaccination 250 (67% responders, Figure 5C ), with only a 2.3-fold decline in geomean frequency from the peak (0.077% to 0.033%, 251 Figure 5C ). Both acute and memory CD8 + T cell responses were dominated by IFN-producing cells (Figures 5B-C and  252 S4A-B, I), the majority of which co-expressed GzB ( Figure S4I ). The majority of the memory spike-specific CD8 + T cells 253 exhibited an effector memory (TEM) surface phenotype ( Figure S4J) . 254 For the BNT162b2 vaccine, IFN + and total ICS + CD8 + T cell responses also peaked after the 2 nd immunization 255 (T3 73% and 85% responders, respectively Figures 5B-C) . Memory CD8 + T cells were maintained out to 6 months 256 after BNT162b2 vaccination (64% responders, Figure 5C ), with only a 2-fold decline in geomean frequency ( Figure  257 5C). Multifunctional spike-specific memory CD8 + T cells were more common in mRNA-1273 compared to BNT162b2 258 vaccinees (Figures 5C and S4H, I) , with the responses dominated by IFN + cells (Figures 5C and S4H-I) . Overall, spike-259 specific CD8 + T cell acute and memory responses to BNT162b2 were similar to mRNA-1273 but slightly lower in 260 frequency and multifunctionality. 261

The fraction of CD8 + T cell responders to Ad26.COV2.S was lower than both mRNA vaccines (67% compared  262 to 87% and 85%, Figure 5C ). Nevertheless, Ad26.COV2.S spike-specific CD8 + T cell frequencies were relatively stable 263 through 6 months post-vaccination (Figures 5B-C and S4A-B) and geomean frequencies of memory CD8 + T cells after 264

Ad26.COV2.S vaccination were comparable to both mRNA vaccines at 6 months ( Figures 5B-C and S4A-B) . The 265 estimated t1/2 for memory CD8 + T cells at 6 months post-mRNA1273 or Ad26.COV2.S was greater than 1 year (t1/2 266 449 and 381 days, respectively. 95% Cls: 101 to ∞ days, and 89 to ∞ days, respectively). 267

For the NVX-CoV2373 vaccine, spike-specific ICS + memory CD8 + T cells were observed in 10% to 50% of 268 donors (T4 and T5, Figure 5C ). There were minimal multifunctional CD8 + T cells ( Figure 5C and S4H-I). 269

Overall, memory CD8 + T cell frequencies and response rates were similar between mRNA-1273, BNT162b2, 270

and Ad26.COV2.S immunizations. Low but detectable memory CD8 + T cells were observed in some individuals after 271 NVX-CoV2373 immunization. CD8 + T cell responses to all COVID-19 vaccines were dominated by IFN-producing cells. 272

No differences in IFN MFI were observed between memory CD8 + T cells generated for each of the vaccines ( Figure  273 S4D). All vaccines elicited IFN + memory CD8 + cells ( Figure S4C ) and AIM + memory CD8 + cells ( Figure S4G ) at 274 frequencies comparable to, or slightly higher than, frequencies observed in SARS-CoV-2 recovered individuals at six 275 months ( Figure S4C , G).

Spike-and RBD-specific B cell memory to four COVID-19 vaccines 278

Next, we sought to characterize and compare the development of B cell memory across the 4 different 279 COVID-19 vaccines. For that, we utilized spike and RDB probes to identify, quantify and phenotypically characterize 280 memory B cells from vaccinated subjects at 3.5 (T4) and 6 months (T5) after immunization ( Figures 6A-B and S5A) . 281

Spike-specific and RBD-specific memory B cells were detected in all vaccinated subjects at 6 months ( Figures 6C-D) .

RBD-specific memory B cells comprised 15 to 20% of the spike-specific memory B cell population, on average ( Figure  283 S5B). Immunization with mRNA-1273 or BNT162b2 led to higher frequencies of spike-specific and RBD-specific 284 memory B cells compared to Ad26.COV2.S and NVX-CoV2373 at 3.5 and 6 months (each p<0.01. Figures 6C-D) .

Memory B cell responses to the 4 vaccines did not exhibit the same kinetics as the antibody responses. The 286 frequency of spike-specific memory B cells increased over time, (mRNA-1273, p=0.017; BNT162b2, p=0.0018, 287

Ad26.COV2.S, p=0.021. Figure 6C ). RBD-specific memory B cell frequencies increased at 6 months after mRNA-1273 288

(1.7-fold, p=0.024), BNT162b2 (2.2-fold, p=0.06), Ad26.COV2.S (2.1-fold, p=0.06), and NVX-CoV2373 (3.05-fold, 289 p=0.033) ( Figure 6D ). 290 RBD-specific memory B cell isotypes were mostly comparable among the different vaccines, with an average 291 distribution of 83% IgG, 2.5% IgM, and 2.2% IgA at 6 months (donut graphs, Figure 6D and Figure S5C) ; however, 292

IgA + RBD-specific memory B cells were higher at 3.5 months in mRNA vaccinees compared to Ad26.COV2.S (mRNA-293 1273 p=0.003. BNT162b2 p=0.04. Figure 6D) . Phenotypically, activated memory B cells (CD21 -CD27 + ) comprised 49% 294 of spike-specific memory B cells after mRNA vaccination (Figure S6B ), which was significantly higher than observed 295

for Ad26.COV2.S or NVX-CoV2373 (mRNA-1273 or BNT162b2 vs. Ad26.COV2.S, p<0.0001. mRNA-1273 vs. NVX-296

CoV2373, p=0.0027; BNT162b2 vs. NVX-CoV2373 p=0.0038 (Figure S6B ), and these differences persisted at 6 months 297 ( Figure 6E) . Reciprocally, the representation of classical memory B cells (CD21 + CD27 + ) was lower in response to 298 mRNA vaccines ( Figure 6F and Figure S6C ). The frequency of atypical memory B cells (CD21 -CD27 -) was low and 299 comparable among vaccines ( Figure S6D) . To further qualitatively compare memory B cells across vaccine platforms,  300  we assessed CD71, CXCR3, CD95, and CD11c expression on spike-specific memory B cells. No differences in CD11c  301 were observed ( Figure S6I ). CD71 + memory B cells were more common at 3.5 months in response to mRNA vaccines 302 than Ad26.COV2.S or NVX-CoV2373 (T4 Figure 6G) , with higher expression on activated memory B cells ( Figure S6E ).

Considering that CD71 is a proliferation marker of B cells, this may reflect greater continuing production of memory 304 B cells in response to mRNA vaccines at 3.5 months compared to Ad26.COV2.S and NVX-CoV2373 vaccines. At 6 305 months, the frequency of CD71 + spike-specific memory B cells remained elevated for mRNA-1273 ( Figure S6F ).

CXCR3 + spike-specific memory B cell frequencies were substantially higher in response to Ad26.COV2.S 307 compared to the other vaccine platforms (mRNA-1273 p<0.001, BNT162b2 p<0.001, NVX-CoV2373 p=0.008. Figure  308 6H) and remained elevated at 6 months ( Figure S6G ). In previously-infected individuals, ~40% of spike-binding 309 memory B cells were CXCR3 + at 6 months PSO, which was significantly higher than the ~7% CXCR3 + observed from 310 mRNA vaccinees at 6 months ( Figure S6G ). Since CXCR3 expression during viral responses can be driven by the 311 transcription factor Tbet, we assessed the frequency of Tbet + spike-specific memory B cells. There was a trend 312 towards higher Tbet expression in Ad26.COV2.S vaccinees ( Figure S6J ). Atypical memory B cells or "age-associated 313 B cells" are often Tbet + and express CXCR3 (Rubtsova et al., 2015) . However, atypical memory B cells are rare in 314 response to these COVID-19 vaccines by the CD21 -CD27cell definition ( Figure S6D) . Furthermore, while CD95 + spike-315 specific memory B cells were increased in Ad26.COV2.S vaccinees ( Figure S6H ), CD11c or CD95 expression was not 316 selectively observed on CXCR3 + compared to CXCR3spike-binding memory B cells ( Figure S6K and L); and, by 317 performing quadrant gating, the majority of the spike-specific memory B cell enrichment in Ad26.COV2.S vaccinees 318 was CXCR3 + CD95 -CD11ccells ( Figure S6M and N) . In sum, using multiple approaches to characterize the CXCR3 + 319 memory B cells, and to classify atypical B cells, our data suggest that atypical memory B cells are uncommon in 320 response to any of the COVID-19 vaccines analyzed here, whereas CXCR3 + memory B cells are substantially generated 321 in response to Ad26.COV2.S immunization or SARS-CoV-2 infection. 322

Lastly, the frequencies of spike-specific and RBD-specific memory B cells at 6 months post-vaccination were 323

comparable to the frequencies found in previously-infected subjects at 6 months ( Figures 6I-J) , indicating robust 324 memory B cell development in response to each of the four COVID-19 vaccines. 325 326

Multiparametric comparisons across vaccine platforms 327 We performed multiparametric analyses, utilizing both correlation matrixes and principal component 328 analysis (PCA) to assess the relative immunogenicity of the four vaccines (Figure 7 and S7) . Considering all 329 parameters of vaccine antigen-specific immune responses at 6 months after mRNA (mRNA-1273 and BNT162b2) or 330

Ad26.COV2.S vaccination (Figures S7A-B) , we observed strong correlations between spike IgG, RBD IgG, and 331 neutralizing antibody titers ( Figures 7A-B and 7F ). Neutralizing antibody titers correlated with spike-specific and 332 RBD-specific memory B cells for mRNA vaccinees at 6 months ( Figures 7A, C-D) . Antibody levels and memory CD4 + T 333 cells were significantly associated in mRNA vaccinees by multiple metrics (Figures 7A and 7E) . In contrast, no 334 relationship was observed between antibodies and memory CD8 + T cells ( Figure 7A ). Memory CD4 + T cells and CD8 + 335 T cells were significantly cross-correlated in mRNA vaccinees ( Figure S7A ). For Ad26.COV2.S vaccination, no 336 significant correlations were detected at 6 months between antibodies, memory B cells, memory CD4 + T cells, or 337 memory CD8 + T cells, which may be related to the smaller cohort size (Figures 7A and 7G-I) . 338

Next, we tested for relationships between early immune responses and immune memory (Figures 7J-N,  339 S7C-H). Peak post-2 nd mRNA immunization cTfh CD4 + T cells were strongly associated with 6-month antibody levels 340 (Figures 7J-L , and S7C-D), providing an early indicator of long-term humoral immunity. Early RBD IgG titers after the 341 1 st mRNA immunization were positively associated with 6-month RBD-specific memory B cell frequencies ( Figure  342 S7G-H). For both mRNA and Ad26.COV2.S, peak ICS + CD4 + and CD8 + T cell responses significantly cross-correlated 343 (T3, Figure 7J ). Overall, these observations suggest that early peak CD4 + T cells responses had a lasting effect on the 344 humoral response. 345

PCA mapping was performed using 3.5-month ( Figure S7I ) and 6-month ( Figure 7O ) post-vaccination data. 346

PCA discriminated mRNA-1273 and Ad26.COV2.S, indicating these two vaccines generated distinct immunological 347 profiles ( Figure 7O ). BNT162b2 largely developed the same profile as mRNA-1273 but with more heterogeneity. 348 NVX-CoV2373 generated an immune memory profile overlapping with that of mRNA and adenoviral vectors ( Figure  349 7O). Prominent immunological features distinguishing between mRNA and Ad26.COV2.S were CXCR3 + spike-specific 350 memory B cells, ICS + memory CD4 + T cells, CD71 + memory B cells, and spike IgG (Figure 7O and S7I) . Notably, 351

neutralizing antibody titers and CXCR3 + spike-specific memory B cells were correlated for Ad26.COV2.S vaccinees 352 J o u r n a l P r e -p r o o f (r=0.44, p=0.04) but not mRNA vaccinees (mRNA-1273, p=0.25. BNT162b2, p=0.79. Figure 7P) Ad26.COV2.S and NVX-CoV2373, with implications for understanding the protection against COVID-19 associated 362

with each of the vaccines. A strength of this study is that the samples from different vaccine platforms were obtained 363 from the same blood processing facility, from the same geographical location, and were analyzed concomitantly, 364

utilizing the same experimental platform. 365

In the present study, antibody responses were detected in 100% of individuals. At 6 months post-immunization, 366

the neutralizing antibody titer hierarchy between the vaccines was mRNA-1273~BNT162b2~NVX-367

CoV2373>Ad26.COV2.S. These serological data are consistent with previous reports for single vaccines ( platforms, and with longitudinal data and single-cell cytokine expression resolution providing insights regarding CD4 + 383 T cell subpopulations between the vaccines. Interestingly, multifunctional CD4 + T cells were observed most 384 frequently after mRNA-1273 immunization, and GzB + early CD4-CTLs represented a substantial fraction of the 385 memory CD4 + T cells after mRNA-1273, BNT162b2, or NVX-CoV2373 vaccination. cTfh memory cells were 386

represented as a substantial fraction of CD4 + T cell memory for each of the 4 vaccines, consistent with these vaccine 387 platforms being selected for their ability to induce antibody responses. Memory CD4 + T cell responses were also 388 compared to infected individuals, demonstrated that each vaccine was successful in generating circulating spike-389 specific CD4 + T cell memory frequencies similar to or higher than SARS-CoV-2 infection, though of course infection 390 also generates responses to other viral antigens. 391

The two mRNA vaccines and Ad26.COV2.S induced comparable acute and memory CD8 + T cell frequencies. protein-based vaccine, IFN + memory CD8 + T cell frequencies after NVX-CoV2373 were lower than the other vaccine 397 platforms assessed, but it was notable that NVX-CoV2373 generated spike-specific CD8 + T cell memory in a significant 398 fraction of individuals, and the IFN + spike-specific memory CD8 + T cell frequencies were similar at 6 months between 399 NVX-CoV2373 immunizations and SARS-CoV-2 infection. Across the antigen-specific immune metrics assessed, mRNA vaccines were consistently the most 426 immunogenic, with levels higher than or equal to that of Ad26.COV2.S and NVX-CoV2373 vaccines for each immune 427

response. NVX-CoV2373 elicited CD4 + T cell memory and neutralizing antibody titers comparably to the mRNA 428

vaccines. The responses induced by the Ad26.COV2.S were generally lower but relatively stable. The mRNA vaccine 429 platforms were associated with substantial declines in neutralizing antibody titers over 6 months, while memory 430

CD4

observations appear to be consistent with the relatively high degree of protection maintained against 432 hospitalizations with COVID-19 after these vaccines over 6 months, and the differential VE reported between mRNA 433 COVID-19 vaccines and Ad26.COV2.S. These results of detailed immunological evaluations, coupled with analyses of 434 VE data published for the various vaccine platforms, may also be relevant for other vaccine efforts. 435 436 LIMITATIONS OF STUDY 437 We did not evaluate recognition of variants, as this was evaluated in independent studies from our laboratories and 438

others (Flemming, We thank Gina Levi and the LJI clinical core for assistance in sample coordination and blood processing. This project 445 has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, 446

National We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other 465 types of diversity in the recruitment of human subjects. We worked to ensure that the study questionnaires were 466 prepared in an inclusive way. One or more of the authors of this paper self-identifies as an underrepresented ethnic 467 minority in science. One or more of the authors of this paper received support from a program designed to increase 468 minority representation in science. While citing references scientifically relevant for this work, we also actively 469 worked to promote gender balance in our reference list. T cell responses induced by COVID-19 vaccines at T1, T2, T3, T4, and T5.   631 Representative gating strategy of spike-specific AIM + CD8 + T cells (E) and spike-specific CD8 + T cells were measured by AIM assay: 632 AIM + CD69 + and CD137 + after stimulation with spike MP (F).

(G) Comparison of spike-specific CD8 + T cell responses (AIM + CD69 + CD137 + ) between COVID-19 vaccinees at 185 ± 6 days post-634 vaccination and SARS-CoV-2-exposed subjects 170 to 195 days PSO. Figure  725 1B. For baseline determinations, for a subset of donors, blood samples were collected before vaccination (T1). T2 726 was 2 weeks (targeting 15 ± 3 days) after the 1 st immunization. T3 was 2 weeks after the 2nd immunization, or 727 approximately day 45 after the 1 st immunization for the 1-dose Ad26.COV2.S. T4 was 3.5 months after the 1 st dose. 728 T5 was 6 months after the 1 st dose. An overview of all samples analyzed in this study is provided in Figure 1C . 729 Both cohorts of mRNA vaccinees (mRNA-1273, Pfizer/BioNTech BNT162b2) received two doses of the vaccine 730 (28 and 21 days apart, respectively). In the case of the Novavax NVX-CoV2373, we advertised locally to recruit 731 subjects who had participated in an investigational NVX-CoV2373 trial conducted in the San Diego region, where two 732 intramuscular 5-μg doses of NVX-CoV2373 or placebo were administered 21 days apart (Clinicaltrials.gov). The NVX-733

CoV2373 trial was structured such that donors initially received two doses of placebo or vaccine in a blinded manner 734 and were then provided two doses of the opposite (vaccine or placebo), such that all participants were vaccinated. 735

The gap between dose 2 and dose 3 for the LJI recruited cohort was 53±38 days ( Figure 1B) Exclusion criteria 754

Before analyzing the entire data set for our cohort, we generated exclusion criteria as follows: subjects who tested 755 positive for RBD and neutralization antibodies at baseline were excluded (one subject, mRNA-1273); subjects with 756 no baseline sample available and whose RBD and neutralization antibody reached the peak after first-dose 757 immunization (indicative of memory from previous infection) and were nucleocapsid (NC) antibody-positive were 758 also excluded as previously infected subjects (one subject, mRNA-1273). In addition, any time points following a 759 confirmed COVID-19 booster immunization were excluded for any subject (five subjects, BNT162b2, two 760

Ad26.COV2.S, two NVX-CoV2373 The next day, plates were blocked with 3% milk in phosphate-buffered saline (PBS) containing 0.05% Tween-20 for 782

1.5 hours at room temperature. Plasma was heat-inactivated at 56°C for 30 to 60 min. Plasma was diluted in 1% milk 783 containing 0.05% Tween-20 in PBS starting at a 1:3 dilution followed by serial dilutions by three and incubated for 784 1.5 hours at room temperature. Plates were washed five times with 0.05% PBS-Tween-20. Secondary antibodies 785

were diluted in 1% milk containing 0.05% Tween-20 in PBS. Anti-human IgG peroxidase antibody produced in goat 786 (Sigma A6029) was used at a 1:5,000 dilution. Plates were read on Spectramax Plate Reader at 450 nm, and data 787 analysis was performed using SoftMax Pro. 788

End-point titers were plotted for each sample, using background-subtracted data. Negative and positive 789 controls were used to standardize each assay and normalize across experiments. A positive control standard was 790 created by pooling plasma from 6 convalescent COVID-19 donors to normalize between experiments. The limit of 791 detection (LOD) was defined as 1:3 of IgG. The limit of quantification (LOQ) for COVID-19 vaccinated individuals were 792 established based on pre-vaccinated individuals (timepoint 1) and set as the titer at which 95% of pre-vaccinated 793 samples (T1) fell below the dotted line (Figures 2A-B) . Titers, LOD, and LOQ were calibrated to the WHO International 794

Reference Panel for anti-SARS-CoV-2 spike, RBD, and nucleocapsid binding antibody units per milliliter (WHO 795 BAU/mL). For Spike IgG, the LOD was 0.20 with a LOQ of 1.024 (Figures 2A and 2D) . For RBD IgG, the LOD was 0.83 796 with a LOQ of 7.12 (Figures 2B and 2E) . For NC IgG, the LOD was 0.68 with a LOQ of 30.48 ( Figure S1A ). 797

For comparison among mRNA-1273, BNT162b, and Ad26.COV2.S over the entire 6+ month time period, 798 log10 transformed end-point titers (WHO BAU/mL) were used to generate area under the curve (AUC) for each donor 799 (Figures S1B-D) . Donors with only 1 timepoint excluded. If there was no (T1), T1 was set as the LOD ET (BAU/mL). 800

Correction factors for AUCs were determined by the number of time points and normalized to compare donor to 801

donor. For comparison among mRNA-1273, BNT162b, Ad26.COV2.S, and NVZ-CoV2373 over the 3.5 months to 6 802 months period, log10 transformed end-point titers (WHO BAU/mL) were used to generate area under the curve (AUC) 803

for each donor (Figures S1E-G) . To calculate the spike IgG half-life (t1/2) for the memory time point, a simple linear regression was performed 807 using log2-transformed T4-T5 paired data. The mean and 95% Cl of t1/2 were described in the Results section. 808 809

Pseudovirus (PSV) Neutralization Assay 810

The PSV neutralization assays in samples from vaccinated subjects were performed as previously described ( incubated with serially diluted human heat-inactivated plasma at 37°C for 1-1.5 hours before addition to confluent 817 VERO cell monolayers. Cells were incubated for 16 hours at 37°C in 5% CO2 then fixed in 4% paraformaldehyde in 818 PBS pH 7.4 (Santa Cruz, Cat. No. sc-281692) with 10 µg/ml of Hoechst (Thermo Scientific, Cat. No. 62249), and imaged 819 using a CellInsight CX5 imager to quantify the total number of cells and infected GFP expressing cells to determine 820 the percentage of infection. Neutralization titers or inhibition dose 50 (ID50) were calculated using the One-Site Fit 821

Log IC50 model in Prism 9.3 (GraphPad). As internal quality control to define the variation inter-assay, a pooled 822 plasma (secondary standard) from 10 donors who received the mRNA-1273 vaccine was included across the PSV 823 neutralization assays. Samples that did not reach 50% inhibition at the lowest serum dilution of 1:20 were considered 824 as non-neutralizing and the values were set to 19. PSV neutralization titers were done with two replicates per 825 experiment. We included the WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (20/268) to 826 calibrate our PSV neutralization titers. The WHO IU calibrated neutralization ID50 (cID50-IU/mL) was graphed in 827

figures. The limit of detection was calculated as 10.73 IU/mL. 828 829

T cell experiments 830

All T cell assays were carried out by two independent investigators (JMT and CMR) on the same model analyzer 831

(Cytek Aurora). To ensure comparability between results, all samples were distributed in a blinded fashion and 832

subjects which received different vaccines were distributed between the batches. All timepoints (T1-T5) from a given 833 donor were run in the same experiment, including a positive and negative control for each donor. Furthermore, each 834 independent experiment included a sample of the same control donor, with known SARS-CoV-2 specific CD4 and 835

CD8 T cell reactivity. Deviation from the expected reactivity resulted in repetition of the experiment. Details of the 836 T cell assays are provided below. After all experiments were run, experimentalists were unblinded to allow of vaccine 837 specific analysis and data interpretation. 838 839

Spike megapool (Spike MP) 840 We have previously developed the MP approach to allow simultaneous testing of a large number of epitopes, as 841

reported Spike-specific CD4 + T cells were measured as a percentage of OX40 + CD137 + AIM + or OX40 + sCD40L + AIM + and spike-855 specific CD8 + T cells were measured as a percentage of CD69 + CD137 + AIM + CD8 + T cells after stimulation of PBMCs 856 from subjects vaccinated with the Spike MP. Also, spike-specific circulating T follicular helper (cTfh) cells 857 (CXCR5 + OX40 + CD40L + , as a percentage of CD4 + T cells) were defined by the AIM assay. Briefly, prior to the addition 858 of the Spike MP, PBMCs were blocked at 37°C for 15 min with 0.5 µg/ml anti-CD40 mAb (Miltenyi Biotec). Then, cells 859

were incubated at 37°C for 24 hours in the presence of fluorescently labeled chemokine receptor antibodies (anti-860 CCR6, CXCR5, CXCR3, and CCR7) and the Spike MP (1 µg/ml) in 96-wells U-bottom plates, as previously table S1  868 and a representative gating strategy of spike-specific CD4 + and CD8 + T cells using the AIM assay is shown in Figure  869 S2, respectively. 870

Spike-specific CD4 + and CD8 + T cells were measured as background (DMSO) subtracted data, with a minimal 871 DMSO level set to 0.005%. Response > 0.02% and a stimulation index (SI) > 2 for CD4 + and > 0.03% and SI > 3 for 872 CD8 + T cells were considered positive. The limit of quantification (LOQ) for antigen-specific CD4 + T cell responses 873 (0.03%) and antigen-specific CD8 + T cell responses (0.05%) was calculated using the median two-fold standard 874 deviation of all negative controls. 875 876

Intracellular cytokine staining (ICS) assay 877

The strategy of spike-specific CD4 + and CD8 + T cells producing IFN, TNF, IL-2 and/or GzB using the ICS assay is shown 890

in Figures 4A and 5A . 891

To define the spike-specific T cells by the ICS assay, we gated the cytokine-or GzB-producing cells together 892 with the expression of iCD40L or CD69 on CD4 + or CD8 + T cells, respectively (Figures 4A and 5A) . Then, a Boolean 893 analysis was performed to define the multifunctional profiles on define the multifunctional profiles of spike-specific T cells, all positive background-subtracted data (> 0.005% and a 898 SI > 2 for CD4 + T cells and CD8 + T cells) was aggregated into a combined sum of antigen-specific CD4 + or CD8 + T cells 899

based on the number of functions. Values higher than the LOQ (0.01%) were considered for the analysis of the 900 multifunctional spike-specific T cell responses. The average of the relative CD4 + and CD8 + T cell responses was 901 calculated per donor and visit to define the proportion of multifunctional spike-specific T cell responses with one, 902 two, three, and four functions (Figures 4B, 5C, S3A M=cor(DataFrame, method="spearman", use = "pairwise.complete.obs") 939

MP=cor.mtest(DataFrame, method="spearman", use = "pairwise.complete.obs", conf.level=0.95, exact=FALSE) 940 corrplot(M, p.mat = MP$p, method = 'square', tl.col="black", tl.cex = 0.7, tl.srt = 45, cl.align="l", type = 'lower', 941

sig.level = c(0.001, 0.01, 0.05), pch.cex = 0.7, insig = 'label_sig', pch.col = 'white') 942

The "DataFrame" is the data from each correlation matrix shown in figure 6 , collected and organized in spreadsheet. 943

The codes for PCA analysis are as follows: 944

res.pca=PCA(na.omit(MP), scale = TRUE) 945 fviz_eig(res.pca, addlabels = TRUE) 946 fviz_pca_biplot(res.pca, label ="var", labelsize = 3, repel= TRUE, geom.ind = "point", pointsize= 4, col.ind = 947

Group$Vaccine, palette = c("darkgreen", "blue", "red", "purple"), col.var = "black", alpha.var = 0.5, addEllipses = 948 TRUE, ellipse.alpha=0, select.var=list(name=c("RBD IgG", "Spike IgG", "nAbs", "MBC", "aMBC", "cMBC", "CXCR3+ 949 MBC", "AIM2+ CD4", "ICS+ CD4", "ICS+ CD8")), ellipse.level=0.8, legend.title = "Groups", invisible = "quali", title="") 950 951

QUANTIFICATION AND STATISTICAL ANALYSIS 952

Cytometry data was analyzed using T1 T2 T3 T4 T5   T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5   10 T1 T2 T3 T4 T5   T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5   0 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 0.01 D   T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T cells   T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 A   T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 Longitudinal analysis of T cell, B cell, and antibody response to four different COVID-19 vaccines in humans, representing three different vaccine technologies, identifies different quantities and quality of CD4 + T cell, CD8 + T cell, and antibody response elicited by mRNA-1273, BNT162b2, Ad26.COV2.S and NVX-CoV2373. Antibody levels decline, while memory T cells and B cells were comparatively stable.

Homologous and Heterologous Covid-19 Booster Vaccinations

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. N Engl 970

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. 976

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 978 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

T Follicular Helper Cell Biology: A Decade of Discovery and Diseases

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia

Antibody Persistence through 6 Months after the Second Dose of mRNA-996 1273 Vaccine for Covid-19

Efficacy and Safety of NVX-CoV2373 in Adults in the United States 999 and Mexico

Cross reactive T cells hold up against Omicron

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Divergent SARS CoV-2 Omicron-reactive T-and B cell responses 1007 in COVID-19 vaccine recipients

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical 1010 trial

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants 1013 of concern

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-1016 19 Disease and Unexposed Individuals

BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell 1019 memory phenotype

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Count on us: T cells in SARS-CoV-2 infection and vaccination

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S 1029 immunogenicity in a variant-dependent manner

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Neutralizing antibody levels are highly predictive of immune protection from 1038 symptomatic SARS-CoV-2 infection

Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and 1044 immunocompromised individuals

Long-lasting germinal center responses to a priming immunization with continuous proliferation 1047 and somatic mutation. bioRxiv

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous 1050 COVID-19 Diagnosis -California

Covid-19 Vaccines over a 9-Month Period in North Carolina

Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron

How COVID vaccines 1058 shaped 2021 in eight powerful charts

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-1061 reactive T cells

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 1066 antibody

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response 1069 in humans

Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine 1072 Dose. bioRxiv

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 1075 and Ad26

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 1078 and Ad26.COV2.S COVID-19 vaccines

Risk of infection, hospitalisation, and death up to 9 months after 1080 a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden

Coronavirus vaccine candidate updates

Migrant memory B cells 1084 secrete luminal antibody in the vagina

Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal 1087 antiviral IgA

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. 1096

A guide to vaccinology: from basic principles to new developments

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections 1101 in the UK

Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity

Covid-19 Vaccine Effectiveness in New York State

Age-Associated B Cells: A T-bet-Dependent 1109

Effector with Roles in Protective and Pathogenic Immunity

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations 1112 with Age and Disease Severity

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

From vaccines to memory and back

Comparative Effectiveness of Moderna

Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions -United 1124

Adaptive immunity to SARS-CoV-2 and COVID-19

Comparison of SARS-CoV-2 Antibody 1128 Response Following Vaccination With BNT162b2 and mRNA-1273

SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha 1132 to Omicron

Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated 1135 individuals

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated 1138 health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl 1141

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates